Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer

CompletedOBSERVATIONAL
Enrollment

70

Participants

Timeline

Start Date

April 1, 2017

Primary Completion Date

April 1, 2018

Study Completion Date

April 1, 2018

Conditions
Colorectal Cancer
Interventions
DRUG

Folfirinox + cetuximab

Cetuximab 250 mg/m² iv infusion for 2h, Oxaliplatin 85 mg/m² administered as an iv infusion for 2h Elvorine 200 mg/m² administered as an iv infusion for 2h, Irinotecan 180 mg/m² iv infusion, 5FU 400 mg/m2 bolus then 5FU 2,400 mg/m² iv infusion for 46h D1=D15 (12 cycles max)

Trial Locations (1)

34298

Institut régional du cancer de Montpellier, Montpellier

All Listed Sponsors
collaborator

Merck Serono International SA

INDUSTRY

lead

Institut du Cancer de Montpellier - Val d'Aurelle

OTHER

NCT03914170 - Folfirinox + Cetuximab Chemotherapy, in First Line, With Wild RAS and According to BRAF Status in Metastatic Colorectal Cancer | Biotech Hunter | Biotech Hunter